Apabetalone

Generic Name
Apabetalone
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H22N2O5
CAS Number
1044870-39-4
Unique Ingredient Identifier
8R4A7GDZ1D
Background

Apabetalone has been investigated for the treatment of Diabetes, Atherosclerosis, and Coronary Artery Disease.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of Apabetalone in Subjects with Long -COVID

Phase 2
Not yet recruiting
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Drug: Apabetalone
First Posted Date
2024-09-10
Last Posted Date
2024-09-19
Lead Sponsor
Resverlogix Corp
Target Recruit Count
200
Registration Number
NCT06590324
Locations
🇯🇴

The Speciality Hospital, Amman, Jordan

🇸🇦

MNGHA- King Abdulaziz Hospital, Al Mubarraz, Saudi Arabia

🇦🇪

Al Kuwait Hospital, Dubai, United Arab Emirates

Apabetalone for Pulmonary Arterial Hypertension

Phase 2
Not yet recruiting
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Placebo
Drug: Apabetalone
First Posted Date
2021-06-07
Last Posted Date
2023-04-18
Lead Sponsor
Laval University
Target Recruit Count
72
Registration Number
NCT04915300
Locations
🇨🇦

IUCPQ-UL, Québec, Canada

An Open-Label Study of Apabetalone in Covid Infection

Phase 2
Terminated
Conditions
COVID-19 Infection
Interventions
Other: Standard of care
Drug: Apabetalone
First Posted Date
2021-05-20
Last Posted Date
2023-11-18
Lead Sponsor
Resverlogix Corp
Target Recruit Count
1
Registration Number
NCT04894266
Locations
🇨🇦

University of Alberta, Edmonton, Alberta, Canada

Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

Early Phase 1
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Apabetalone
First Posted Date
2018-08-31
Last Posted Date
2022-04-25
Lead Sponsor
Steeve Provencher
Target Recruit Count
7
Registration Number
NCT03655704
Locations
🇨🇦

IUCPQ-UL, Quebec City, Quebec, Canada

🇨🇦

Peter Lougheed Center, Calgary, Alberta, Canada

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Phase 1
Not yet recruiting
Conditions
Kidney Failure, Chronic
Interventions
Drug: apabetalone
Drug: Placebos
First Posted Date
2017-05-19
Last Posted Date
2023-11-15
Lead Sponsor
Resverlogix Corp
Target Recruit Count
44
Registration Number
NCT03160430

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

First Posted Date
2015-10-26
Last Posted Date
2021-08-20
Lead Sponsor
Resverlogix Corp
Target Recruit Count
2425
Registration Number
NCT02586155
Locations
🇭🇷

Clinical Hospital Sveti duh, Zagreb, Croatia

🇧🇪

AZ Turnhout, Turnhout, Belgium

🇮🇱

Kaplan Medical Center, Rehovot, Israel

and more 210 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy